1. In Vivo

Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets

Sandoz, Teva And Viatris Adopt Differing Strategies With Regard To Innovation

 
• By Dave Wallace

With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures.

Winning hand at blackjack, betting concept
Which firms will end up with a winning hand? • Source: Shutterstock

Competitive pressures are par for the course in the off-patent industry. The generics and biosimilars sector is built on the premise of multi-source competition, meaning that multiple players in the market will always be vying for share, working out how to keep costs as low as possible, and surviving on margins that are often slim.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo